Asparaginase
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparagine
Erwinia
Drug Hypersensitivity
Aspartate-Ammonia Ligase
Dimethyldithiocarbamate
Lactate dehydrogenase-elevating virus
Glutamine
Injections, Intramuscular
Aspartate Ammonia-Lyase
Polyethylene Glycols
Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS.
Aspartic Acid
Cytarabine
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Remission Induction
Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. (1/487)
PURPOSE: The CNS is an important sanctuary site in childhood acute lymphoblastic leukemia (ALL). CSF asparagine concentration reflects asparaginase systemic pharmacodynamics. We evaluated the time course of CSF asparagine depletion in children with ALL during and after a course of Escherichia coli asparaginase. PATIENTS AND METHODS: Thirty-one children (24 newly diagnosed and seven at relapse) received E coli asparaginase 10,000 IU/m2 intramuscularly three times weekly for six and nine doses, respectively, as part of multiagent induction chemotherapy. CSF asparagine levels were measured before, during, and after asparaginase dosing. RESULTS: The percentage of patients with undetectable (< 0.04 micromol/L) CSF asparagine was 3.2% (one of 31 patients) at baseline, 73.9% (17 of 23) during asparaginase therapy, and 56.3% (nine of 16) 1 to 5 days, 43.8% (seven of 16) 6 to 10 days, 20.0% (two of 10) 11 to 30 days and 0% (zero of 21) more than 30 days after asparaginase therapy. The proportion of patients with depleted CSF asparagine was higher during asparaginase therapy than at baseline (P < .001), 11 to 30 days (P = .003), and more than 30 days after asparaginase therapy (P < .001). Median CSF asparagine concentrations were 4.42 micromol/L before, less than 0.04 micromol/L during, and less than 0.04 micromol/L at 1 to 5 days, 1.63 micromol/L at 6 to 10 days, 1.70 micromol/L at 11 to 30 days, and 5.70 micromol/L at more than 30 days after asparaginase therapy, respectively. CSF depletion was more common in patients with low baseline CSF asparagine concentrations (P = .003). CONCLUSION: CSF asparagine concentrations are depleted by conventional doses of E coli asparaginase in the majority of patients, but they rebound once asparaginase therapy is completed. (+info)Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross-resistant chemotherapy: Japan Clinical Oncology Group Study 8702. Lymphoma Study Group. (2/487)
BACKGROUND: Patients with acute lymphocytic leukemia (ALL) and those with lymphoblastic lymphoma (LBL) have overlapping clinical and immunophenotypic features and they have been treated with the same or very similar chemotherapy regimens. The goal of this multi-institutional phase II trial was to evaluate the therapeutic efficacy of a short-term, six-drug chemotherapy regimen for adult patients with untreated ALL or LBL. METHODS: Forty-six eligible patients, 41 with ALL and five with LBL, were treated with a short-term (planned total therapy duration; 36-38 weeks), simplified chemotherapy program; two courses of VEPA-L (vincristine, cyclophosphamide, prednisolone, doxorubicin, I-asparaginase plus intrathecal methotrexate and prednisolone) followed by four courses of M-VEPA (methotrexate plus VEPA), without the traditional maintenance therapy using daily 6-mercaptopurine and weekly methotrexate. RESULTS: Thirty-six (78%; 95% confidence interval 64-89%) of the 46 eligible patients achieved complete remission (CR). Among the 36 patients who achieved CR, four (11%) died of treatment complications, 26 (72%) relapsed and six (17%) remain alive in continuous CR. The median survival for all 46 eligible patients is 14 months and the median disease-free survival (DFS) for the 36 patients who achieved CR is 11 months. The estimate of the proportion of survival at 7 years of all 46 eligible patients is 15% at a median follow-up time of 96 months and that of DFS of the 36 patients achieving CR is 17% at a median follow-up time of 93 months. Subgroup analysis showed that an elevated serum C-reactive protein (CRP) level, age of 30 years or older, the presence of B-symptom and T-cell phenotype were likely to be associated with shortened survival. Although the observed CR rate (78%) is within the range of satisfaction, the long-term survival rate (15%) is inferior to those of published programs incorporating maintenance therapy. CONCLUSIONS: A fraction of adult patients with ALL or LBL are curable with a short-term, six-drug chemotherapy regimen. However, this simplified therapy of shorter duration cannot be recommended. (+info)Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study. (3/487)
BACKGROUND AND OBJECTIVE: In a prior study, primary resistant acute lymphoblastic leukemia (RES-ALL) was observed in 11 of 176 (6%) adult patients treated with a four drug regimen (IVAP), its incidence being higher in T-cell or Philadelphia (Ph) chromosome/BCR-ABL rearrangement positive ALL cases with a blast cell count >25x10(9)/L (RES-ALL rate 19%, p=0.04). Aiming to minimize this percentage of resistant disease, fractionated cyclophosphamide (f-CY) was then added to the IVAP regimen. DESIGN AND METHODS: Study 08-96 was a prospective, collaborative phase II trial carried out at eight general hospital centers specialized in the care of hematologic malignancies. Historical IVAP-treated patients served as a retrospective control group. All consecutive, untreated patients (>15 years) with a diagnosis of ALL or advanced-stage lymphoblastic lymphoma (LBL) were eligible. RES-ALL was defined as the persistence of >5% ALL cells in the bone marrow 28-40 days after the start of the IVAP regimen (idarubicin 10 mg/m(2)/d on days 1 and 2; vincristine 2 mg on days 1, 8 and 15; L-asparaginase 6,000 U/m(2) on alternate days 3 6 from day 8; prednisone 60 mg/m(2)/d on days 1-21). In the new study, two f-CY schedules were sequentially adopted: CY 150 or 75 mg/m(2)/bd, given for 4 consecutive days before IVAP (f-CY 1200 or 600, expressing total CY dose in mg/m(2)). RESULTS: Eighty-eight patients were evaluable (age range 15-74 years, blast count 0-240x10(9)/L, 14 T-lineage, 74 B-lineage, 13 Ph/BCR-ABL+). The first 39 patients received the f-CY 1200 schedule, 22 patients received f-CY 600, and the last 27 patients were not given any f-CY. These changes were dictated by the results of interim analyses of the f-CY groups (RES-ALL rate not reduced, myelotoxicity increased). Altogether, compared with the historical IVAP and no f-CY groups, the incidence of RES-ALL was not decreased by the addition of f-CY 1200/600 in B-lineage ALL, regardless of Ph/BCR-ABL expression and blast count. However, none of 14 T-ALL cases in the new study had RES-ALL (8 in f-CY groups, 5 of whom with >25x10(9)/L blast cells), compared to 5/39 (13%, overall) or 4/21 (19%, with >25x10(9)/L blast cells) among the control cases. Owing to small sample size, this difference was not statistically significant. INTERPRETATION AND CONCLUSIONS: This preliminary experience suggests that T-ALL may be more sensitive than B-lineage ALL to an early therapy including f-CY. The hypothesis could be tested in a larger clinical trial. (+info)Non-Hodgkin's lymphoma in children: results of treatment with LSA2-L2 protocol. (4/487)
The results obtained with very intensive treatment in previously untreated patients early in the disease are encouraging, and we hope will change the philosophy of most investigators that even in far advanced disease such as those with marrow metastases or multiple primary sites, one can still obtain complete regression at all tumour sites within 1 to 1 1/2 months from onset of therapy by combined treatment with multiple chemotherapeutic agents and radiation therapy to one or more sites. (+info)Acute lymphoblastic leukaemia: cyclical chemotherapy with three combinations of four drugs (COAP-POMP-CART regimen). (5/487)
Forty-two adults and children with previously untreated acute lymphoblastic leukaemia (ALL) were entered into a programme of chemotherapy in which three combinations, each of four drugs were administered in a predetermined cyclical rotation together with cranial irradiation and intrathecal injections of methotrexate. Forty-one patients (98%) entered remission and no patient developed neuroleukaemia. Relapse of ALL occurred in 10 patients, and three patients died during remission, while eight patients stopped treatment after two and a half years and have remained in remission for two to 26 months. Comparison of remission and survival experience in this mixed group of children and adults with the experience of children treated at Memphis and in the Medical Research Council's UKALL-I trial showed no significant differences. On the other hand, analysis by prognostic factors showed that neither age nor blast cell count at presentation had any adverse effect in patients treated in this study. No relapses occurred in nine patients with blast cell counts greater than 20 x 109/1 at presentation. This regimen is effective treatment for ALL and may be of special value in patients with poor prognoses. The regiment has not as yet proved superior for the treatment of children with ALL who do not have adverse prognostic features. (+info)Applications of synchrotron radiation to protein crystallography: preliminary results. (6/487)
X-ray diffraction photographs of protein single crystals have been obtained using synchrotron radiation produced by an electron-positron storage ring. The diffracted intensities observed with this unconventional source are a factor of at least 60 greater than those obtained with a sealed x-ray tube using the same crystal and instrumental parameters. Diffraction data have been collected by the precession method to higher resolution and using smaller protein crystals than would have been possible with a conventional source. The crystal decay rate in the synchrotron beam for several proteins appears to be substantially less than that observed with Ni-filtered Cu radiation. The tunable nature of the source (which allows selective optimization of anomalous contributions to the scattering factors) and the low angular divergence of the beam make the source very useful for single crystal protein diffraction studies. (+info)Hypersensitivity to tobacco antigen. (7/487)
A glycoprotein of molecular weight 18,000 was purified from saline extracts of cured tobacco leaves by ammonium sulfate fractionation, chromatography on Sephadex G-25 and continuous-flow preparative electrophoresis on polyacrylamide gel. Twelve of 31 volunteers (6/15 smokers and 6/16 nonsmokers) exhibited immediate cutaneous hypersensitivity (wheal and flare reactions) when injected intracutaneously with 2 mug of this material. Immunochemically similar material was demonstrated in, and purified from, cigarette smoke condensate and cigarette smoke. The concentration in cigarette smoke condensate ("tar") was determined to be 1.8-3.6 mg/g. Antigenically crossreactive material was also demonstrated in eggplants, green peppers, potatoes, and tomatoes, which, like tobacco, are members of the family Solanaceae. (+info)Binding of Clostridium botulinum C2 toxin to asparagine-linked complex and hybrid carbohydrates. (8/487)
Clostridium botulinum C2 toxin is a binary toxin composed of an enzymatic subunit (C2I) capable of ADP-ribosylating actin and a binding subunit (C2II) that is responsible for interaction with receptors on eukaryotic cells. Here we show that binding of C2 toxin depends on the presence of asparagine-linked carbohydrates. A recently identified Chinese hamster ovary cell mutant (Fritz, G., Schroeder, P., and Aktories, K. (1995) Infect. Immun. 63, 2334-2340) was found to be deficient in N-acetylglucosaminyltransferase I. C2 sensitivity of this mutant was restored by transfection of an N-acetylglucosaminyltransferase I cDNA. C2 toxin sensitivity was reduced after inhibition of alpha-mannosidase II. In contrast, Chinese hamster ovary cell mutants deficient in sialylated (Lec2) or galactosylated (Lec8) glycoconjugates showed an increase in toxin sensitivity compared with wild-type cells. Our results show that the GlcNAc residue linked beta-1,2 to the alpha-1,3-mannose of the asparagine-linked core structure is essential for C2II binding to Chinese hamster ovary cells. (+info)
Antitumor activity of L-asparaginase from Erwinia Carotovora from against different leukemic and solid tumours cell lines
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli...
Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase |...
L-asparaginase II Production by Escherichia coli - Digital Library
Desensitization to pegaspargase in children with acute lymphoblastic l by Keith J. August, Sana Farooki et al.
Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors. - Semantic Scholar
Asparaginase - Side Effects, Uses, Dosage, Overdose, Pregnancy, Alcohol | RxWiki
Asparaginase facts, information, pictures | Encyclopedia.com articles about Asparaginase
Biomolecules | Free Full-Text | Tackling Critical Catalytic Residues in Helicobacter pylori L-Asparaginase
Pharmacokinetic and pharmacodynamic properties of calaspargase pegol E by Anne Angiolillo, Reuven J. Schore et al.
Donate Blood and Platelets - Dana-Farber Cancer Institute | Boston, MA
Asparaginase escherichia coli Disease Interactions - Drugs.com Interactions Checker
Measurement of Serum l-Asparagine in the Presence of l-Asparaginase Requires the Presence of an l-Asparaginase Inhibitor |...
Dana-Farber Cancer Institute - Wikipedia
A Study of Children With Refractory or Relapsed ALL - CheckOrphan
Dana-Farber launches NFCR Center for Therapeutic Antibody Research and E...( BOSTONThe Dana-Farber Cancer Institute ...)
Challenge Awards-Class of 2017 - PCF
JCI -
A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug l-asparaginase
Nasal cancer prognosis: 14-3-3 epsilon predictor for asparaginase treatment - Ezine - separationsNOW.com
Gordon J. Freeman, PhD - Dana-Farber Cancer Institute | Boston, MA
Dana-Farber Cancer Institute | Mesothelioma Cancer Centers
New Test Predicts CLLs Sensitivity to Experimental Drug ( Dana-Farber Cancer Institute scientists...)
How is Gene Therapy Being Used to Treat Cancer? | Dana-Farber Cancer Institute
Challenge Awards-Class of 2017 | Prostate Cancer Foundation
ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase - Full Text View -...
Plus it
Leucmies aigus lymphoblastiques
Asparaginase | Roswell Park Comprehensive Cancer Center
Find Asparaginase (5000IU) alternatives online at lowest price in India - PillsBills.com
ASPARAGINASE 5000 - Pret Pret
A Drug Monitoring Study on PEG-asparaginase Treatment in Children Diagnosed Acute Lymphoblastic Leukaemia - Full Text View -...
Asparaginase Erwinia chrysanthemi - Side Effects, Uses, Dosage, Overdose, Pregnancy, Alcohol | RxWiki
Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry (v.6, #4) | www.chemweb.com
Central nervous system prophylaxis | definition of central nervous system prophylaxis by Medical dictionary
Ansa subclavia | definition of ansa subclavia by Medical dictionary
The Effect of Combination of Steroid and L-Asparaginase on Hyperglycemia in Children with Acute Lymphoblastic Leukemia (ALL)
Asparaginase (Erwinia chrysanthemi) Monograph for Professionals - Drugs.com
Minerva Pediatrica 2000 April;52(4) - Minerva Medica - Journals
Minerva Pediatrica 2001 April;53(2) - Minerva Medica - Journals
Plus it
When is an Antipsychotic Not an Antipsychotic? When its an Antileukemic | Dana-Farber Cancer Institute
Oncologia integrata in radioterapia: evidenze scientifiche e gestione degli effetti collaterali
Ansa Cervicalis
Calcium and adenosine triphosphate control of cellular pathology: asparaginase-induced pancreatitis elicited via protease...
Ask the Expert Tip on Treatment for Stage III Lung Cancer
Click to print
ERYTECH Announces Resubmission of European Marketing Authorization Application for GRASPA in Acute Lymphoblastic Leukemia |...
Nurse Practitioner Jobs in Milford, MA | Dana-Farber Cancer Institute Careers
Nurse Practitioner Jobs in Brookline, MA | Dana-Farber Cancer Institute Careers
Cancer Care Nova Scotia - Drug Monograph for ASPARAGINASE ERWINIA
MTHFR C677T polymorphisms and childhood acute lymphoblastic leukemia: a meta-analysis
Correction: Bim Polymorphisms: Influence on Function and Response to Treatment in Children with Acute Lymphoblastic Leukemia |...
Cancer Types - Mihaela Catalina Stanciu Foundation for Life
Meet the Director > Yale Cancer Center | Yale School of...
A Targeted Therapy Next in Line for Biomarker-based Cancer Drug Approval? - CANCER RESEARCH Catalyst
Xconomy: Xcelerate Keynote Bios
Tunisian migrants sew mouths shut in protest on Lampedusa - English - ANSA.it
ANSA McAL Group Vacancies August 2021 - Sweet TnT Magazine
JCI -
Galactose protects against cell damage in mouse models of acute pancreatitis
Cancer drug resistance strategy uncovered - Oral Cancer News
Immuno-Oncology Biomarkers | Immuno Oncology Summit 2019
Obesity, Physical Inactivity Linked With Risk for Certain Molecular Subtype of Colorectal Cancer
PPT - New Clinical Trials in Prostate Cancer PowerPoint Presentation - ID:63801
Germline |em|RABL3|/em| Mutation May Increase Risk of Pancreatic Cancer Development - The ASCO Post
Dr. Schoenfeld on Low-Dose Radiation Plus Immunotherapy in Head and Neck Cancer
Expert Point of View: Monoclonal Antibody Promising in Multiple Myeloma - The ASCO Post
Weight, Lack of Exercise Raise Risk of Colorectal Cancer - Cakehealth
Plus it
Researchers offer sweeping view of prostate cancer genome, yielding deep insights into cancer growth - Healthcanal.com :...
Outsmarting Breast Cancer With Evolving Therapies
Plus it
Cancer Medicine & Hematology | conferenceSurveyMOC-2019|1367
Cancer Medicine & Hematology | conferenceSurveyMOC-2019|6391
Inivata highlights new clinical data on InVision™ platform in advanced NSCLC - Cambridge Innovation Capital
Highlighted Research
Targeted drug shows promise in rare advanced kidney cancer | EurekAlert! Science News
Practical Implications of the RELAY Trial in EGFR+ NSCLC
Journal Highlights
Dr. Laurie Cohen, MD - Boston, MA | Pediatric Endocrinology
The Point Blog - January 2013 - Christian Medical & Dental Associations
Reagent request
CHIMERAS: The immortality paradox
A new computational method makes gene expression analyses from RNA-Seq data more accurate | RNA-Seq Blog
Video | Dr. Richard M Stone, MD | Boston, MA | Vitals
Éric A. Cohen - Wikipedia
Alyssa ODriscoll, Salt Lake City professional. Expert Executive Director at Sarcoma Alliance | Ladders Expert Network
Markets slide worldwide amid us budget battle
Breaking Down Misconceptions About Glioblastoma
P01 Incidence and clinical associations of acute pancreatitis in children aged 0-14 years in the united kingdom | Archives of...
Fungal isolate
Flammulina velutipes creates asparaginase. Plinabulin is a fungal isolate derivative currently being researched for anticancer ...
Bayard D. Clarkson
Coli L-asparaginase in man". Cancer. 25 (2): 253-278. doi:10.1002/1097-0142(197002)25:2. 3.0.CO;2-U. PMID 4905153. S2CID ...
ASRGL1
L-asparaginase is an enzyme that in humans is encoded by the ASRGL1 gene. The ASRGL1 protein consists of 308 amino acids and is ... "Entrez Gene: ASRGL1 asparaginase like 1". Li, Wenzong; Cantor, Jason R.; Yogesha, S. D.; Yang, Shirley; Chantranupong, Lynne; ... The ASRGL1 enzyme has both L-asparaginase and beta-aspartyl peptidase activity and may be involved in the production of L- ... Bush LA, Herr JC, Wolkowicz M, Sherman NE, Shore A, Flickinger CJ (2002). "A novel asparaginase-like protein is a sperm ...
Dickeya dadantii
ERWINAZE- asparaginase injection, powder, lyophilized, for solution drug label/data at Daily Med from U.S. National Library of ... Anonymous (2012). "Asparaginase erwinia chrysanthemi (erwinaze) for all". Medical Letter on Drugs and Therapeutics. 54 (1388): ... Most noble of its contributions is an enzyme, asparaginase, being used in conjunction with other chemotherapeutic agents for ... coli derived asparaginase Elspar or pegaspargase (Oncaspar). Secondly, with a strong governmental push towards increasing ...
Morpheein
Jerebzoff-Quintin, Simonne; Jerebzoff, Stephan (1985). "L-Asparaginase activity in Leptosphaeria michotii. Isolation and ... "Crystal Structure and Allosteric Regulation of the Cytoplasmic Escherichia coli l-Asparaginase I". Journal of Molecular Biology ...
Industrial enzymes
Lanvers-Kaminsky, Claudia (2017-03-01). "Asparaginase pharmacology: challenges still to be faced". Cancer Chemotherapy and ...
Medicinal fungi
Shrivastava A, Khan AA, Shrivastav A, Jain SK, Singhal PK (2012). "Kinetic studies of L-asparaginase from Penicillium digitatum ... Penicillium is a potential source of the leukemia medicine asparaginase. Some countries have approved Beta-glucan fungal ...
Leukemia
For children with low-risk ALL, standard therapy usually consists of three drugs (prednisone, L-asparaginase, and vincristine) ... other drug plans may include L-asparaginase or cyclophosphamide. ...
Sheldon Schuster
"Selective apoptosis of natural killer-cell tumours by l-asparaginase". British Journal of Haematology. 130 (6): 860-868. doi: ...
Aspergillus niger
"Solid-State Fermentation vs Submerged Fermentation for the Production of l-Asparaginase". Advances in Food and Nutrition ...
Bacillus isolates
Bacillus is utilized in the production of the chemotherapy medicine L-asparaginase. Bacillus subtilis is utilized in the ... a bacterium used to produce the chemotherapy medicine asparaginase Fungal isolates Medicinal molds Sponge isolates Streptomyces ...
Bromothymol blue
... has been used in conjunction with phenol red to monitor the fungal asparaginase enzyme activity with phenol ... ISBN 978-0-470-40753-0. "Isolation and screening of L-asparaginase free of glutaminase and urease from fungal sp". researchgate ... "A comparative rapid and sensitive method to screen l-asparaginase producing fungi". Journal of Microbiological Methods. 102: 66 ...
Streptomyces tendae
Kavitha, A; Vijayalakshmi, M (2009). "Optimization and purification of L-asparaginase produced by Streptomyces tendae TK-VL_333 ...
Fructose-asparagine
FraE is specific for F-Asn and cannot function as a general periplasmic asparaginase like ansB. fraA encodes a transporter of ... fraE encodes the periplasmic fructose-asparaginase FraE that removes ammonia from F-Asn to form fructose-aspartate (F-Asp). ... Mutations in fraE do not prevent F-Asn utilization due to redundancy conferred by the ansB gene that codes for the asparaginase ... an asparaginase homolog, contributes to fructose-asparagine but not asparagine utilization". Journal of Bacteriology. 199 (22 ...
Genome-wide CRISPR-Cas9 knockout screens
... who noted that genes associated with asparaginase sensitivity failed to score in their genome-wide screen of asparaginase- ... 2019) used this method to identify a synthetic lethal interaction between the chemotherapy drug asparaginase and two genes in ... April 2019). "Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias". Cancer Cell. ...
Pegaspargase
... is a modified version of the enzyme asparaginase which has undergone PEGylation. It works by breaking down the ...
Artificial cell
The first enzyme studied under artificial cell encapsulation was asparaginase for the treatment of lymphosarcoma in mice. This ... "The in vivo effects of semipermeable microcapsules containing L-asparaginase on 6C3HED lymphosarcoma". Nature. 229 (5280): 117- ...
Lymphoma in animals
The most common treatment is a combination of cyclophosphamide, vincristine, prednisone, L-asparaginase, and doxorubicin. Other ...
Hyperglycemia
1994). "Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia". J ... L-asparaginase, and antipsychotics. The acute administration of stimulants such as amphetamines typically produces ...
Azaserine
... asparagin)ase". Biochemistry International. 12 (3): 413-20. PMID 3707592. (Articles with short description, Short description ...
Maillard reaction
This can be discouraged by heating at a lower temperature, adding asparaginase, or injecting carbon dioxide. In the cooking ...
James P. Allison
Insolubilization of L-Asparaginase by covalent attachment to nylon tubing (Ph.D.). The University of Texas at Austin. OCLC ... Allison, James Patrick (1973). Studies on bacterial asparaginases: I. Isolation and characterization of a tumor inhibitory ...
Asparagine
In reaction that is the reverse of its biosynthesis, asparagine is hydrolyzed to aspartate by asparaginase. Aspartate then ...
Asparagine synthetase
As a result, L-asparaginase is a common chemotherapy drug utilized in the treatment of ALL and may have applications in other ... For example, in mouse models, 24 hours after exposure to L-asparaginase, tumors resistant to the depletion responded with 5- to ... However, the opposite effect is visible in cases of asparaginase resistant cancers. In these resistant cancers, the effect of ... It has been further demonstrated in mouse model systems that repeated subculturing of L-asparaginase sensitive tumor cells in ...
SurE, survival protein E
SurEstructural domain has a similar topology to the N-terminal protein domain of the glutaminase/asparaginase family. The C- ...
Acrylamide
Pre-treatment of potato slices by asparaginase prior to frying reduced the acrylamide contents in the processed chips up to 81 ... structural modeling and characterization of a novel glutaminase-free L-asparaginase from Cobetia amphilecti AMI6". ...
Monomorphic epitheliotropic intestinal T cell lymphoma
Gentille C, Qin Q, Barbieri A, Ravi PS, Iyer S (2017). "Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T- ...
Aspartylglucosaminidase
N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase is an enzyme that in humans is encoded by the AGA gene. Aspartylglucosaminidase ...
Cobetia amphilecti
The halotolerant Cobetia amphilecti AMI6 produces glutaminase-free L-asparaginase (CobAsnase) with a molecular mass of 37 kDa ...
Vincristine
It is also used to induce remission in ALL with dexamethasone and L-Asparaginase, and in combination with prednisone to treat ...
Asparaginase Erwinia Chrysanthemi Injection: MedlinePlus Drug Information
Asparaginase Erwinia Chrysanthemi Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before taking asparaginase erwinia chrysanthemi,. *tell your doctor and pharmacist if you are allergic to asparaginase erwinia ... asparaginase [Elspar] or pegaspargase [Oncaspar]). Asparaginase erwinia chrysanthemi is an enzyme that interferes with natural ... Asparaginase erwinia chrysanthemi comes as a powder to be added to fluid and injected into a muscle by a doctor or nurse in a ...
Asparaginase - Wikipedia
Asparaginase is an enzyme that is used as a medication and in food manufacturing. As a medication, L-asparaginase is used to ... Type I L-asparaginase protein may use the morpheein model of allosteric regulation. Normal asparaginase costs less than its ... The most common use of asparaginases is as a processing aid in the manufacture of food. Asparaginases are used as a food ... March 2002). "A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase ...
FDA approves asparaginase erwinia chrysanthemi (recombinant) for leukemia and lymphoma | FDA
Oncology News Burst FDA approves asparaginase erwinia chrysanthemi (recombinant) for leukemia and lymphoma ... FDA approves asparaginase erwinia chrysanthemi (recombinant) for leukemia and lymphoma * Resources for Information , Approved ... When replacing a long-acting asparaginase product, the recommended dosage of Rylaze is 25 mg/m2 administered intramuscularly ... The main efficacy outcome measure was demonstration of the achievement and maintenance of nadir serum asparaginase activity ( ...
Erwinaze (asparaginase Erwinia chrysanthemi) dosing, indications, interactions, adverse effects, and more
... asparaginase Erwinia chrysanthemi), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy ... encoded search term (asparaginase Erwinia chrysanthemi (Erwinaze)) and asparaginase Erwinia chrysanthemi (Erwinaze) What to ... Substitution for native E. coli asparaginase: 25,000 IU/m² IM/IV for each scheduled dose of native E. coli asparaginase ... Substitution for native E. coli asparaginase: 25,000 IU/m² IM/IV for each scheduled dose of native E. coli asparaginase ...
PRIME PubMed | Effect of L-asparaginase on acrylamide mitigation in a fried-dough pastry model
Effect of L-asparaginase on acrylamide mitigation in a fried-dough pastry model. Download Prime PubMed App to iPhone, iPad, or ... AcrylamideAmino AcidsAsparaginaseColorCookingDietary ProteinsDietary SucroseFlourFood AnalysisFood ContaminationFood Technology ... Effect of L-asparaginase on acrylamide mitigation in a fried-dough pastry model.. Mol Nutr Food Res. 2009 Dec; 53(12):1532-9.MN ... Effect of L-asparaginase On Acrylamide Mitigation in a Fried-dough Pastry Model. Mol Nutr Food Res. 2009;53(12):1532-9. PubMed ...
Asparaginase Market - Download Summary Form
Pharmacokinetics and Immunogenicity of the First Doses of PEG-Asparaginase -An ALLTogether Pilot Study | Clinical Research...
Pharmacokinetics and Immunogenicity of the First Doses of PEG-Asparaginase -An ALLTogether Pilot Study ... In both cases, Asparaginase is inactivated. It is well known that truncation of Asparaginase treatment due to inactivation ... Pharmacokinetics and Immunogenicity of the First Doses of PEG-Asparaginase -An ALLTogether Pilot Study * ... To approach understanding Asparaginase dynamics and hypersensitivity in ALL patients it is important to examine the ...
CAS # 9015-68-3, L-Asparaginase - chemBlink
Synthetic Lethality of Wnt Pathway Activation and Asparaginase for Cancer Therapy | Gerstner Sloan Kettering Graduate School of...
Pediatric Non-Hodgkin Lymphoma Medication: Antineoplastics, Other, Antineoplastics, Monoclonal Antibodies, PD-1/PD-L1...
IMSEAR at SEARO: L-asparaginase related hyperglycemia.
... only one out of ten patients developed hyperglycemia E-coli-L-asparaginase was replaced by Erwinia asparaginase in two patients ... L-asparaginase is a valuable chemotherapeutic agent used in the induction of remission and improvement of long term survival in ... Hyperglycemia was observed after a mean of five doses of L-asparaginase (range 2-10). Seven of fourteen patients had ... L-asparaginase related hyperglycemia. Indian Journal of Cancer. 1993 Jun; 30(2): 72-6. ...
L-asparaginase
Search
Webinar: 1670 - Live Q&A: Online CME course-Management of asparaginase-related toxicities in the treatment of by Kenes
Table 2 - Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness,...
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. ...
Search
NDC Active Ingredient Asparaginase Erwinia Chrysanthemi
The NDC database has 1 products with the active ingredient Asparaginase Erwinia Chrysanthemi. ... NDC Products with Asparaginase Erwinia Chrysanthemi. NDC. Proprietary Name. Non-Proprietary Name. Dosage Form. Route Name. ... Asparaginase. Injection, Powder, Lyophilized, For Solution. Intramuscular; Intravenous. Porton Biopharma Limited. ACTIVE. ... How many products in the NDC database contain Asparaginase Erwinia Chrysanthemi?. The NDC database has 1 products with the ...
Asparaginases
... are cell cycle-specific and act during the G1phase. They include: · asparaginase · pegaspargase. ... After administration, asparaginase remains inside the blood ves-sels, with minimal distribution elsewhere. The metabolism of as ... Asparaginase drugs may interact with other drugs. Asparaginase and pegaspargase may reduce the effectiveness of methotrexate. ... Asparaginases are cell cycle-specific and act during the G1phase. They include: · asparaginase · pegaspargase. ...
A-Z Drug Index for Prescription and OTC Medications
Possible Interaction: Asparaginase and Glucosamine - SUPP.AI by AI2
FDA Approves Asparaginase Erwinia Chrysanthemi for Leukemia and Lymphoma | ONS Voice
... asparaginase erwinia chrysanthemi (recombinant)-rywn (RylazeTM) as a component of a ... ... When replacing a long-acting asparaginase product, the recommended dosage of asparaginase erwinia chrysanthemi (recombinant)- ... Patients received asparaginase erwinia chrysanthemi (recombinant)-rywn intramuscularly at various dosages. The main efficacy ... View full prescribing information for asparaginase erwinia chrysanthemi (recombinant)-rywn.. The review was conducted under ...
Optimization of fermentation medium to maximize the production of recombinant human asparaginase in Escherichia coli through...
Optimization of fermentation medium to maximize the production of recombinant human asparaginase in Escherichia coli through ... Aim: Recombinant human asparaginase (rhASP) from Escherichia coli is an important therapeutic enzyme used in the treatment of ... Optimization of fermentation medium to maximize the production of recombinant human asparaginase in Escherichia coli through ...
L-Asparaginase Injection Exporter,L-Asparaginase Injection Supplier,Manufacturer
Trader of L-Asparaginase Injection From Surat, Gujarat, India. ... PEG L-Asparaginase is an antineoplastic drug. This medication ... How to use Asparaginase Solution, Reconstituted (Recon Soln). This medication is given by injection into a muscle, or under the ... Asparaginase is used to treat acute lymphocytic leukemia (ALL). It works by starving tumor cells of needed nutrients and ...
Science of Childhood Cancer Lecture Series - St. Jude Children's Research Hospital
Lymphoblastic Lymphoma Trial in Chengdu, Shanghai (Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide...
Totally, 3 doses of PEG-asparaginase (Pegylated-asparaginase) are applied in this group. ... Totally, 11 doses of PEG-asparaginase are applied in this group.. Second look biopsy/resection is indicated for patients ... Additional, high dose L-asparaginase was reported to improve disease-free survival for patients with ALL. The event free ... Drug: Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase. Dexamethasone 20mg/m2/day, d1-5; Cytarabine 2000mg/m2/dose, ...
Health Product InfoWatch - March 2018 - Canada.ca
Isolation and Characterization of Glutaminase-free L-asparaginase Produced by Staphylococcus sp. MGM1 | Ebrahimipour |...
Isolation and Characterization of Glutaminase-free L-asparaginase Produced by Staphylococcus sp. MGM1 ... Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: ... L-asparaginase is an important therapeutic enzyme used in combination with other drugs for therapy of Acute Lymphoblastic ... Nguyen, H. A., Su, Y., Zhang, J. Y., Antanasijevic, A., Caffrey, M., Schalk, A. M., … Lavie, A. (2018). A Novel l-Asparaginase ...
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia New | Cochrane...
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia New answers are ... Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia New. In Cochrane ... Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia New is a topic ... "Prophylaxis of Thromboembolism During Therapy With Asparaginase in Adults With Acute Lymphoblastic Leukaemia New." Cochrane ...
VincristinePegaspargaseRecombinantErwinazeEnzymeReceiving asparaginase erwinia chrysanthemiHypersensitivityInjectionEscherichiaElsparNadir serum asparaginase activityDoses of PEG-AsparaginaseRylazeHyperglycemiaReactions to asparaginaseErwinaseAsparagine to aspartic acid and ammoniaTherapyOncasparChemotherapeuticChildren with acute lymphoblSupply of asparagineDoseIngredientsAminoCoagulationPatientsImmunogenicityDrugsTreatmentTumor cellMedicationAspergillusExtracellular
Vincristine5
- Fourteen patients developed hyperglycemia during induction therapy of acute lymphoblastic leukemia with L-asparaginase, prednisolone, vincristine and daunorubicin. (who.int)
- Concurrent use of asparaginase with prednisone or vincristine in-creases the risk of toxicity. (brainkart.com)
- The patients were all treated with the NOPHO ALL-2008 pediatric protocol, consisting of induction with prednisolone, vincristine, doxorubicin, and PEG-asparaginase. (medpagetoday.com)
- Patients with standard- and intermediate-risk disease had consolidation with mercaptopurine, vincristine, PEG-asparaginase, and methotrexate. (medpagetoday.com)
- Those with high-risk disease received additional intensive combination chemotherapy, followed by maintenance with mercaptopurine and/or methotrexate, PEG-asparaginase, vincristine, and dexamethasone. (medpagetoday.com)
Pegaspargase10
- tell your doctor if you have or have ever had pancreatitis (swelling of the pancreas), blood clots, or severe bleeding, especially if these happened during treatment with asparaginase (Elspar) or pegaspargase (Oncaspar). (medlineplus.gov)
- Pegaspargase was previously approved in February 1994 for the treatment of patients with ALL who were hypersensitive to native forms of L-asparaginase. (wikipedia.org)
- They include: · asparaginase · pegaspargase. (brainkart.com)
- Asparaginase and pegaspargase capitalize on the biochemical dif-ferences between normal cells and tumor cells. (brainkart.com)
- Asparaginase and pegaspargase help to degrade asparagine to aspartic acid and ammonia. (brainkart.com)
- Pegaspargase is used to treat acute lymphocytic leukemia in pa-tients who are allergic to the native form of asparaginase. (brainkart.com)
- Asparaginase and pegaspargase may reduce the effectiveness of methotrexate. (brainkart.com)
- these happened during treatment with asparaginase (Elspar) or pegaspargase (Oncaspar). (nih.gov)
- Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia (ALL) Consortium Protocol 11-001 assessed efficacy and toxicity of calaspargase pegol (calaspargase), a novel pegylated asparaginase formulation with longer half-life, compared with the standard formulation pegaspargase. (physiciansweekly.com)
- The first approved PEGylated pharmaceuticals were Pegademase bovine (PEGylated bovine adenosine deamidase) as enzyme replacement therapy for severe combined immunodeficiency and Pegaspargase (PEGylated asparaginase) for treatment of acute lymphoblastic leukaemia (1). (ddw-online.com)
Recombinant6
- Spectrila is a recombinant E. coli asparaginase. (wikipedia.org)
- On 30 June 2021, the U.S. Food and Drug Administration (FDA) approved asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in people aged one month or older who have developed hypersensitivity to E. coli-derived asparaginase. (wikipedia.org)
- The FDA granted the application for asparaginase erwinia chrysanthemi (recombinant)-rywn fast track and orphan drug designations. (wikipedia.org)
- On June 30, 2021, the Food and Drug Administration approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. (fda.gov)
- Patients received asparaginase erwinia chrysanthemi (recombinant)-rywn intramuscularly at various dosages. (ons.org)
- Aim: Recombinant human asparaginase (rhASP) from Escherichia coli is an important therapeutic enzyme used in the treatment of malignant cancers. (greenpharmacy.info)
Erwinaze1
- This slideshow reviews asparaginase erwinia chrysanthemi (Erwinaze), indicated for treatment acute lymphoblastic leukemia (ALL) in patients with a hypersensitivity to Escherichia coli-derived asparaginase. (oncologynurseadvisor.com)
Enzyme13
- Asparaginase erwinia chrysanthemi is an enzyme that interferes with natural substances necessary for cancer cell growth. (medlineplus.gov)
- Asparaginase is an enzyme that is used as a medication and in food manufacturing. (wikipedia.org)
- L-asparaginase is an enzyme produced by Escherichia coli that catalyzes the conversion of L-asparagine to aspartic acid. (medscape.com)
- L-asparaginase is an important therapeutic enzyme used in combination with other drugs for therapy of Acute Lymphoblastic Leukemia (ALL). (scimedjournal.org)
- This study was aimed at isolation and identification of a strain with the ability to producing extracellular glutaminase free L-asparaginase from soil and determination of enzyme stability. (scimedjournal.org)
- The optimum pH and temperature for maximum L-asparaginase activity were found at 8 and 35 °C. The enzyme purification showed a single band around 115 kDa on SDS-Page. (scimedjournal.org)
- The optimal activity for the enzyme produced by MGM1 was similar to the physiological conditions of the human body, therefore, further studies on this enzyme would be of great value in finding a new efficient asparaginase enzyme. (scimedjournal.org)
- Enzyme specificity and cytotoxicity of highly purified asparaginase enzyme of frozen seeds of pisum sativum var jof. (journalcra.com)
- Hyderabad: Indian Institute of Technology Hyderabad Researchers working with scientists from National Centre for Polar and Ocean Research (NCPOR), Goa, have isolated Antarctic fungi that contain L-Asparaginase, an enzyme-based chemotherapeutic agent used to treat Acute Lymphoblastic Leukemia. (indiaeducationdiary.in)
- One of the most frequently used chemotherapy drugs to treat ALL is the enzyme L-Asparaginase. (indiaeducationdiary.in)
- The L-Asparaginase enzyme used for chemotherapy is currently derived from commonly found bacteria such as Escherichia coli and Erwinia chrysanthemi. (indiaeducationdiary.in)
- Asparaginase is an enzyme that has been purified from E. coli and Erwinia carotovora. (humpath.com)
- Preserving Catalytic Activity and Enhancing Biochemical Stability of the Therapeutic Enzyme Asparaginase by Biocompatible Multi layered Polyelectrolyte Microcapsules. (mpg.de)
Receiving asparaginase erwinia chrysanthemi1
- If you become pregnant while receiving asparaginase erwinia chrysanthemi, call your doctor. (medlineplus.gov)
Hypersensitivity9
- Efficacy was evaluated in Study JZP458-201 (NCT04145531), an open-label, multi-cohort, multicenter trial in 102 patients with ALL or LBL with hypersensitivity to E. coli -derived asparaginase as a component of a multi-agent chemotherapeutic regimen. (fda.gov)
- During the induction period Asparaginase is an indispensable part of the multiagent treatment, but is often associated with hypersensitivity, either with clinical allergy or silent inactivation. (centerwatch.com)
- To approach understanding Asparaginase dynamics and hypersensitivity in ALL patients it is important to examine the pharmacokinetics of Asparaginase. (centerwatch.com)
- The aim of this study is to identify serological parameters for prediction of hypersensitivity reaction after the first doses of PEG-Asparaginase given intravenously on the ALLTogether protocol. (centerwatch.com)
- In February 2017 it was approved by the NOPHO Board to do more extensive pharmacokinetic studies of IM administered PEG-asparaginase, as it has not been shown if IM or IV is preferably in respect to minimizing the incidence of hypersensitivity. (centerwatch.com)
- HLA alleles associated with asparaginase hypersensitivity in Chinese children. (cdc.gov)
- Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia. (cdc.gov)
- Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity. (cdc.gov)
- Part of combination chemotherapy in the treatment of acute lymphocytic leukemia (ALL) in patients who developed hypersensitivity to E. coli -derived asparaginase. (unboundmedicine.com)
Injection1
- Leading Wholesale Trader of zyrop 4000 injection, terifrac 750 mcg injection, peg l asparaginase injection, merocrit 1gm meropenem injection, 40mg enoxaparin injection and bevacirel 100mg/ 4ml bevacizumab injection from Ahmedabad. (sspharmaceutical.com)
Escherichia2
- Dynamics of a mobile loop at the active site of Escherichia coli asparaginase. (scimedjournal.org)
- Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. (chop.edu)
Elspar1
- One of the E. coli asparaginases marketed under the brand name Elspar for the treatment of acute lymphoblastic leukemia (ALL) is also used in some mast cell tumor protocols. (wikipedia.org)
Nadir serum asparaginase activity2
- The main efficacy outcome measure was demonstration of the achievement and maintenance of nadir serum asparaginase activity (NSAA) above the level of 0.1 U/mL. (fda.gov)
- For IV doses, monitoring pre-dose nadir serum asparaginase activity (NSAA) levels and switch to IM administration if desired NSAA levels are not achieved. (unboundmedicine.com)
Doses of PEG-Asparaginase2
- Totally, 3 doses of PEG-asparaginase (Pegylated-asparaginase) are applied in this group. (clincosm.com)
- Intermediate risk group: patients (stage III or IV or receiving steroids within one week prior to the diagnosis) receive induction protocol I followed by the extracompartmental protocol M, reintensification protocol II, and maintenance for up to a total therapy duration of 104 weeks.Totally, 5 doses of PEG-asparaginase are applied in this group. (clincosm.com)
Rylaze2
- When replacing a long-acting asparaginase product, the recommended dosage of Rylaze is 25 mg/m2 administered intramuscularly every 48 hours for the required duration of asparaginase activity. (fda.gov)
- FDA has approved a new form of asparaginase called Rylaze. (cancer.gov)
Hyperglycemia6
- IMSEAR at SEARO: L-asparaginase related hyperglycemia. (who.int)
- L-asparaginase related hyperglycemia. (who.int)
- Hyperglycemia is a well known side effect of L-asparaginase. (who.int)
- Hyperglycemia was observed after a mean of five doses of L-asparaginase (range 2-10). (who.int)
- During reinduction therapy with the same drugs, only one out of ten patients developed hyperglycemia E-coli-L-asparaginase was replaced by Erwinia asparaginase in two patients one of who had recrudescence on further therapy. (who.int)
- Close monitoring during L-asparaginase therapy for hyperglycemia will enable prompt recognition and early correction and prevent delay in therapy of acute lymphoblastic leukemia. (who.int)
Reactions to asparaginase1
- Learn about therapeutic drug monitoring in ALL treatment and how it can be used to distinguish and manage reactions to asparaginase therapy. (serviervirtualoncology.com)
Erwinase1
- Asparaginase produced by Dickeya dadantii (formerly called Erwinia chrysanthemi) instead is known as crisantaspase (BAN), and is available in the United Kingdom under the brand name Erwinase. (wikipedia.org)
Asparagine to aspartic acid and ammonia1
- L-asparaginase catalyzes the conversion of asparagine to aspartic acid and ammonia. (scimedjournal.org)
Therapy3
- Abnormalities of lipid profile in children with ALL during asparaginase therapy are relatively common. (tau.ac.il)
- Asparaginase (ASNase) therapy has been a mainstay of acute lymphoblastic leukemia (ALL) protocols for decades and shows promise in the treatment of a variety of other cancers. (prinsesmaximacentrum.nl)
- Additional studies will address questions relating to asparaginase and thiopurine therapy, and biological, pharmacogenetic and pharmacokinetic determinants of treatment response. (ukri.org)
Oncaspar1
- Branded formulations (with different chemical and pharmacological properties) available in 1998 include Asparaginase Medac, Ciderolase, and Oncaspar. (wikipedia.org)
Chemotherapeutic3
- L-asparaginase is a valuable chemotherapeutic agent used in the induction of remission and improvement of long term survival in patients with acute lymphoblastic leukemia. (who.int)
- The isolation of L-asparaginase containing fungi from extreme environments could lead to development of new chemotherapeutic treatment methods that have fewer side effects than the existing methods. (indiaeducationdiary.in)
- One example of a current drug with a critically short supply is Erwinia asparaginase, a life-saving chemotherapeutic agent for both children and adults with cancer. (powerpak.com)
Children with acute lymphobl2
- To determine the incidence and clinical consequences of asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia (ALL). (tau.ac.il)
- L. G. Mitchell, M. Andrew and K. Hanna, "A Prospective Cohort Study Determining the Prevalence of Thrombotic Events in Children with Acute Lymphoblastic Leukemia and a Central Venous Line Who Are Treated with L-Asparaginase: Results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study," Cancer, Vol. 97, No. 2, 2003, pp. 508-516. (scirp.org)
Supply of asparagine1
- L-Asparaginase reduces the supply of asparagine, an amino acid that is essential for the synthesis of protein, to cancer cells. (indiaeducationdiary.in)
Dose3
- If you miss an appointment to receive a dose of asparaginase erwinia chrysanthemi, call your doctor right away. (medlineplus.gov)
- Additional, high dose L-asparaginase was reported to improve disease-free survival for patients with ALL. (clincosm.com)
- Serum asparaginase activity (SAA) (≥ 0.1 IU/mL considered therapeutic) was assessed 4, 11, 18, and 25 days after the induction dose and before each postinduction dose. (physiciansweekly.com)
Ingredients1
- tell your doctor and pharmacist if you are allergic to asparaginase erwinia chrysanthemi, any other medications, or any of the ingredients in asparaginase erwinia chrysanthemi powder. (medlineplus.gov)
Amino5
- Asparaginase works by breaking down the amino acid known as asparagine without which the cancer cells cannot make protein. (wikipedia.org)
- By adding asparaginase before baking or frying the food, asparagine is converted into another common amino acid, aspartic acid, and ammonium. (wikipedia.org)
- A dough resembling traditional Spanish rosquillas was used as a model to represent classical fried-dough pastry to investigate the effects of asparaginase and heat treatment on amino acid levels and acrylamide mitigation. (unboundmedicine.com)
- Erwinia carotovora L-asparaginase was conjugated via the epsilon-amino groups of its lysine residues with colominic acid (CA) (polysialic acid) of average molecular mass of 10 kDa by reductive amination in the presence of NaCNBH3. (researchgate.net)
- One common chemotherapy, called L-asparaginase , works for many ALL patients by diminishing an amino acid called asparagine , which ALL cells need to survive. (iu.edu)
Coagulation1
- A. C. Homans, M. E. Rybak, R. L. Baglini, C. Tiarks, M. E. Steiner and E. N. Forman, "Effect of L-Asparaginase Administration on Coagulation and Platelet Function in Children with Leukemia," Journal of Clinical Oncology, Vol. 5, 1987, p. 811. (scirp.org)
Patients2
- Asparaginase is used primarily in combination with standard chemotherapy to induce remission in patients with acute lympho-cytic leukemia. (brainkart.com)
- Patients must be receiving chemotherapy, including asparaginase, and have a central line (a catheter inserted for administration of medications and blood sampling). (ufhealth.org)
Immunogenicity1
- Purification, characterization and immunogenicity assessment of glutaminase free L-asparaginase from Streptomyces brollosae NEAE-115. (scimedjournal.org)
Drugs2
- Asparaginase drugs may interact with other drugs. (brainkart.com)
- According to six articles that were selected, curcumin could enhance the antitumor activity of chemotherapy drugs such as L-asparaginase. (qualitycounts.com)
Treatment8
- It is well known that truncation of Asparaginase treatment due to inactivation reduces survival. (centerwatch.com)
- For many years prolonged Asp treatment for 30 weeks has been part of most protocols worldwide, but a recent Nordic randomized study showed that less asparaginase (8 doses vs 15 doses intramuscularly (IM)) results in the same disease-free survival and significant less toxicity in the less intensive treatment arm (6). (centerwatch.com)
- Pharmacological and clinical evaluation of l-asparaginase in the treatment of leukemia. (scimedjournal.org)
- Lipid abnormalities normalized in all children upon completion of asparaginase treatment. (tau.ac.il)
- We recommend measuring TG before and during asparaginase treatment. (tau.ac.il)
- Cell survival and remaining activity of L20B tumor cell line after treatment with purified asparaginase reduced to 68, 65 and 77% respectively after incubation with purified asparaginase at concentration of 150 µg/ml, while the cell line remaining activity percentage reduced to 66.6, 67.7 and 76µg/ml respectively. (journalcra.com)
- The drug was developed to help alleviate shortages of Erwinia asparaginase, a key part of treatment for children and adults with acute lymphoblastic leukemia. (cancer.gov)
- treatment of asparaginase-induced hepatotoxicity. (biotecnologie2000.com)
Tumor cell1
- against L20B tumor cell line measured at wave length of 450, 492 and 620nm respectively, it showed that's purified asparaginase has maximum inhibitory effect on tumor cell line reached to 33, 33, and 23% growth at 450, 492 and 620nm respectively. (journalcra.com)
Medication1
- As a medication, L-asparaginase is used to treat acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). (wikipedia.org)
Aspergillus1
- Production of L-Asparaginase, an Anticancer Agent, From Aspergillus niger Using Agricultural Waste in Solid State Fermentation. (scimedjournal.org)
Extracellular1
- Conversely, depletion of extracellular asparagine with PEG-asparaginase sensitizes tumors to mitochondrial targeting with phenformin. (nature.com)